Diabetic nephropathy is a chronic, progressive form of kidney disease that develops as a microvascular complication of long-standing diabetes mellitus. It is defined clinically by persistent albuminuria (initially moderately increased/“microalbuminuria,” progressing to severely increased/“macroalbuminuria”) together with a sustained decline in glomerular filtration rate (GFR) and, frequently, rising blood pressure. Mechanistically, chronic hyperglycemia drives glomerular hyperfiltration, mesangial matrix expansion, thickening of the glomerular basement membrane, and the pathognomonic nodular glomerulosclerosis lesions (Kimmelstiel-Wilson nodules) that scar the filtering apparatus and reduce nephron function. Unlike a purely structural term, it is by definition pathological — it does not occur physiologically — though its earliest stages (hyperfiltration, microalbuminuria) can be subclinical and reversible with tight glycemic and blood-pressure control. The clinically and code-relevant subtypes track the underlying diabetes type and the degree of renal impairment: diabetic nephropathy in type 2 DM (E11.21), in type 1 DM (E10.21), and the broader category diabetic chronic kidney disease (E11.22 / E10.22) when a staged CKD is documented. It is most often confused with diabetic chronic kidney disease — nephropathy emphasizes the diabetic glomerular lesion/albuminuria, whereas “diabetic CKD” emphasizes the staged loss of kidney function (N18.-) — and with hypertensive nephropathy, which produces overlapping renal scarring but arises from chronic hypertension rather than hyperglycemia.
The compound entered medical English in the mid-1800s, with nephropathy (noun) built from Greek nephrós (“kidney”) + -pathy (“disease”), paralleling earlier organ-disease coinages. Diabetic (adjective) dates to the 1790s, from diabetes, borrowed through Latin from Greek diabḗtēs — literally “a siphon,” describing the way fluid seemed to pass straight through the body as urine. The modern disease concept was crystallized in 1936, when pathologists Paul Kimmelstiel and Clifford Wilson described the nodular intercapillary glomerulosclerosis lesion that bears their names. The root nephr/o- (“kidney”) connects this term to the entire -nephr root family: nephritis (kidney + inflammation → inflammation of the kidney), nephrosis (kidney + condition → degenerative/non-inflammatory kidney disease), and nephrolithiasis (kidney + stone + condition → kidney stones). The suffix -pathy is highly productive in clinical terminology, appearing in neuropathy, retinopathy, cardiomyopathy, and encephalopathy.
🔀 ALIASES / ALTERNATE TERMS
Diabetic kidney disease (DKD)(adjective/noun form — increasingly the preferred umbrella term in nephrology guidelines; appears as “diabetic kidney disease,” “DKD on biopsy,” “screening for DKD”)
Kimmelstiel-Wilson disease / syndrome(eponymous lay-and-clinical term; refers specifically to the nodular glomerulosclerosis lesion; classic on renal pathology reports)
Intercapillary glomerulosclerosis(the histologic descriptor of the same nodular lesion; “intercapillary” = between glomerular capillary loops)
Diabetic glomerulosclerosis(clinical/pathologic synonym emphasizing the glomerular scarring; coded under the diabetes combination code, not separately as N08.-)
Diabetic chronic kidney disease|Diabetic CKD(closely related staged-function form; E11.22 / E10.22, with an additional N18.- stage code)
Diabetic nephrosclerosis(emphasizes the sclerotic/scarring component; overlaps with hypertensive nephrosclerosis when both are present)
Microalbuminuric (incipient) nephropathy(early etiologic stage — defined by moderately increased albuminuria, 30–300 mg/g; potentially reversible)
Diabetic glomerulopathy(glomerulus-specific descriptor of the structural lesion; used on biopsy/path correlation)
Type 2 diabetic nephropathy(most common form; tied to E11.21)
Type 1 diabetic nephropathy(classic progression model; tied to E10.21)
End-stage diabetic kidney disease(terminal form requiring dialysis/transplant; pair the diabetes code with N18.6)
🔗 RELATED TERMS
Hypertensive nephropathy — the chief differential; produces overlapping glomerular and vascular scarring but is driven by chronic hypertension rather than hyperglycemia. The two frequently coexist; documentation should state the dominant or contributing cause (I12.- / I13.- vs. the diabetes combination code).
glomerulosclerosis — shares the glomerular-scarring process; the nodular (Kimmelstiel-Wilson) pattern is the hallmark of the diabetic form, distinguishing it from focal segmental or diffuse glomerulosclerosis of other causes.
Diabetic chronic kidney disease — the staged-function counterpart; code E11.22/E10.22with an additional N18.- to identify CKD stage (1–5/ESRD).
Albuminuria / proteinuria — the earliest and most important diagnostic markers; persistent moderately-to-severely increased urinary albumin is the screening trigger and a staging variable (the “A” of CGA staging).
Glomerular hyperfiltration — the initiating mechanism; an early, often subclinical rise in GFR that precedes structural damage and albuminuria.
Trophic/vascular support — the diabetic microvascular milieu (endothelial dysfunction, RAAS activation, advanced glycation end-products) that sustains progressive nephron injury.
Apoptosis / podocyte loss — the regulated cellular process underlying podocyte depletion and progressive glomerular barrier failure in this condition.
Diabetic retinopathy — the parallel microvascular complication; its presence strongly supports a diabetic (rather than alternative) cause of kidney disease (E11.31-/E11.32-/E11.34-, etc.).
Diabetic neuropathy — companion microvascular complication frequently coded alongside (E11.40-E11.49); part of the same end-organ damage pattern.
Nephrotic syndrome — diabetic nephropathy is a leading cause of secondary nephrotic-range proteinuria in adults; describe the overlap when edema/hypoalbuminemia are documented.
End-stage renal disease|ESRD — the terminal outcome (N18.6); diabetes is the single most common cause of ESRD in the U.S.
Renal biopsy — the definitive diagnostic procedure when the cause of kidney disease is uncertain or atypical features are present (demonstrates Kimmelstiel-Wilson nodules).
CODING CORNER
🏥 ICD-10-CM CODES
Type 2 Diabetes Mellitus with Kidney Involvement (E11.2x — Most Common)
Code
Description
E11.21
Type 2 diabetes mellitus with diabetic nephropathy
Hemodialysis procedure with single physician/QHP evaluation — dialytic treatment for ESRD
90945
Dialysis procedure other than hemodialysis (eg, peritoneal), single evaluation — alternative renal replacement therapy
⚠️ Coding Note:diabetic nephropathy is captured almost entirely through combination codes in the diabetes chapter (E08–E13) — do not report a separate N-chapter glomerular code (e.g., N08) for the diabetic lesion; the kidney involvement is built into the E_.2x code. (1) Sequencing: code the diabetes-with-nephropathy combination code first, then add the N18.- stage code (per the “use additional code” instruction at E_.22) to specify CKD stage 1–5/ESRD; also add Z79.4 / Z79.84 / Z79.85 for long-term antidiabetic therapy and Z99.2 for dialysis dependence. (2) .21 vs .22 vs .29: “.21 diabetic nephropathy” is the documented Kimmelstiel-Wilson/albuminuric lesion without a stated CKD stage; “.22 diabetic CKD” requires documented CKD and pairs with N18.-; “.29” is for other kidney complications — pick the one the documentation supports rather than defaulting. (3) Undercoding alert: an inpatient profee chart that says only “CKD on a diabetic” or “renal insufficiency, DM2” without linking the two often gets coded as E11.9 + N18.- (no causal link) — query the provider when documentation suggests a relationship but uses non-linking phrasing such as “diabetic with CKD,” “renal disease in setting of diabetes,” or “nephropathy” alone. (4) The ICD-10-CM conventionassumes a causal relationship between diabetes and CKD when both are documented (“with” guideline), so an explicit “due to” is not required — but documentation must still name the CKD stage to reach the most specific E_.22 + N18.- pairing. (5) For prior authorization of SGLT2 inhibitors, GLP-1 agonists, or dialysis access, payers increasingly require the staged code pair (E_.22 + specific N18.-) plus a documented UACR — capture the lab value and stage to support medical necessity.
Crystal's Coder Hub